nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—CYP3A4—bone cancer	0.279	1	CbGaD
Carvedilol—XDH—Carboplatin—bone cancer	0.145	0.35	CbGbCtD
Carvedilol—XDH—Cisplatin—bone cancer	0.124	0.299	CbGbCtD
Carvedilol—XDH—Doxorubicin—bone cancer	0.0833	0.201	CbGbCtD
Carvedilol—CYP2C9—Cisplatin—bone cancer	0.0146	0.0351	CbGbCtD
Carvedilol—ABCB1—Cisplatin—bone cancer	0.0142	0.0341	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—bone cancer	0.00948	0.0229	CbGbCtD
Carvedilol—ABCB1—Methotrexate—bone cancer	0.00919	0.0221	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—bone cancer	0.00894	0.0215	CbGbCtD
Carvedilol—GJA1—periosteum—bone cancer	0.00582	0.232	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—bone cancer	0.00568	0.0137	CbGbCtD
Carvedilol—SELE—connective tissue—bone cancer	0.00118	0.0471	CbGeAlD
Carvedilol—VCAM1—connective tissue—bone cancer	0.00109	0.0433	CbGeAlD
Carvedilol—HIF1A—connective tissue—bone cancer	0.00104	0.0417	CbGeAlD
Carvedilol—GJA1—connective tissue—bone cancer	0.00101	0.0404	CbGeAlD
Carvedilol—ADRB3—connective tissue—bone cancer	0.000929	0.0371	CbGeAlD
Carvedilol—SELE—tendon—bone cancer	0.000812	0.0324	CbGeAlD
Carvedilol—SELE—spinal cord—bone cancer	0.000783	0.0312	CbGeAlD
Carvedilol—VCAM1—tendon—bone cancer	0.000747	0.0298	CbGeAlD
Carvedilol—VCAM1—bone marrow—bone cancer	0.000723	0.0289	CbGeAlD
Carvedilol—VCAM1—spinal cord—bone cancer	0.00072	0.0287	CbGeAlD
Carvedilol—HIF1A—tendon—bone cancer	0.000718	0.0287	CbGeAlD
Carvedilol—GJA1—tendon—bone cancer	0.000697	0.0278	CbGeAlD
Carvedilol—HIF1A—bone marrow—bone cancer	0.000696	0.0278	CbGeAlD
Carvedilol—HIF1A—spinal cord—bone cancer	0.000693	0.0276	CbGeAlD
Carvedilol—Ranolazine—CYP3A4—bone cancer	0.000692	0.347	CrCbGaD
Carvedilol—GJA1—bone marrow—bone cancer	0.000675	0.0269	CbGeAlD
Carvedilol—GJA1—spinal cord—bone cancer	0.000672	0.0268	CbGeAlD
Carvedilol—Tamsulosin—CYP3A4—bone cancer	0.000666	0.334	CrCbGaD
Carvedilol—NDUFC2—tendon—bone cancer	0.000606	0.0242	CbGeAlD
Carvedilol—NDUFC2—bone marrow—bone cancer	0.000587	0.0234	CbGeAlD
Carvedilol—NDUFC2—spinal cord—bone cancer	0.000585	0.0233	CbGeAlD
Carvedilol—VEGFA—tendon—bone cancer	0.00055	0.0219	CbGeAlD
Carvedilol—VEGFA—bone marrow—bone cancer	0.000533	0.0213	CbGeAlD
Carvedilol—VEGFA—spinal cord—bone cancer	0.000531	0.0212	CbGeAlD
Carvedilol—ADRB1—connective tissue—bone cancer	0.00038	0.0152	CbGeAlD
Carvedilol—Propafenone—CYP3A4—bone cancer	0.000379	0.19	CrCbGaD
Carvedilol—Propranolol—CYP3A4—bone cancer	0.00026	0.13	CrCbGaD
Carvedilol—ADRA2A—connective tissue—bone cancer	0.000228	0.00911	CbGeAlD
Carvedilol—PTGS1—connective tissue—bone cancer	0.000215	0.00859	CbGeAlD
Carvedilol—ADRA2C—tendon—bone cancer	0.000197	0.00785	CbGeAlD
Carvedilol—Pollakiuria—Epirubicin—bone cancer	0.000194	0.00152	CcSEcCtD
Carvedilol—KCNH2—bone marrow—bone cancer	0.000193	0.0077	CbGeAlD
Carvedilol—KCNH2—spinal cord—bone cancer	0.000192	0.00767	CbGeAlD
Carvedilol—Photosensitivity reaction—Epirubicin—bone cancer	0.000192	0.0015	CcSEcCtD
Carvedilol—Feeling abnormal—Cisplatin—bone cancer	0.000192	0.0015	CcSEcCtD
Carvedilol—Weight increased—Epirubicin—bone cancer	0.000191	0.00149	CcSEcCtD
Carvedilol—Haematuria—Methotrexate—bone cancer	0.000191	0.00149	CcSEcCtD
Carvedilol—Weight decreased—Epirubicin—bone cancer	0.00019	0.00149	CcSEcCtD
Carvedilol—Hyperglycaemia—Epirubicin—bone cancer	0.00019	0.00148	CcSEcCtD
Carvedilol—ADRA2C—spinal cord—bone cancer	0.00019	0.00757	CbGeAlD
Carvedilol—Angina pectoris—Doxorubicin—bone cancer	0.00019	0.00148	CcSEcCtD
Carvedilol—Pneumonia—Epirubicin—bone cancer	0.000189	0.00147	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—bone cancer	0.000187	0.00146	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000186	0.00145	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—bone cancer	0.000185	0.00144	CcSEcCtD
Carvedilol—Renal failure—Epirubicin—bone cancer	0.000184	0.00144	CcSEcCtD
Carvedilol—Body temperature increased—Cisplatin—bone cancer	0.000184	0.00144	CcSEcCtD
Carvedilol—Urinary tract infection—Epirubicin—bone cancer	0.000182	0.00142	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000181	0.00141	CcSEcCtD
Carvedilol—Haemoglobin—Methotrexate—bone cancer	0.000181	0.00141	CcSEcCtD
Carvedilol—Haemorrhage—Methotrexate—bone cancer	0.00018	0.0014	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—bone cancer	0.00018	0.0014	CcSEcCtD
Carvedilol—Haematuria—Epirubicin—bone cancer	0.000179	0.0014	CcSEcCtD
Carvedilol—Pharyngitis—Methotrexate—bone cancer	0.000179	0.00139	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—bone cancer	0.000178	0.00139	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—bone cancer	0.000178	0.00139	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—bone cancer	0.000177	0.00138	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—bone cancer	0.000176	0.00138	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—bone cancer	0.000176	0.00137	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—bone cancer	0.000176	0.00137	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—bone cancer	0.000176	0.00137	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—bone cancer	0.000175	0.00136	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—bone cancer	0.000173	0.00135	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000172	0.00134	CcSEcCtD
Carvedilol—Hypersensitivity—Cisplatin—bone cancer	0.000172	0.00134	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—bone cancer	0.000171	0.00134	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—bone cancer	0.000171	0.00133	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—bone cancer	0.00017	0.00133	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—bone cancer	0.000169	0.00132	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—bone cancer	0.000169	0.00132	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—bone cancer	0.000169	0.00132	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—bone cancer	0.000168	0.00131	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—bone cancer	0.000168	0.00131	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—bone cancer	0.000168	0.00131	CcSEcCtD
Carvedilol—Asthenia—Cisplatin—bone cancer	0.000167	0.0013	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—bone cancer	0.000167	0.0013	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—bone cancer	0.000166	0.0013	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—bone cancer	0.000166	0.00129	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—bone cancer	0.000166	0.00129	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—bone cancer	0.000165	0.00129	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—bone cancer	0.000163	0.00127	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—bone cancer	0.000163	0.00127	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—bone cancer	0.000163	0.00127	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—bone cancer	0.000162	0.00127	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—bone cancer	0.000162	0.00127	CcSEcCtD
Carvedilol—Diarrhoea—Cisplatin—bone cancer	0.000159	0.00124	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—bone cancer	0.000159	0.00124	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—bone cancer	0.000159	0.00124	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—bone cancer	0.000159	0.00124	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—bone cancer	0.000157	0.00123	CcSEcCtD
Carvedilol—ADRA2A—tendon—bone cancer	0.000157	0.00626	CbGeAlD
Carvedilol—Malnutrition—Methotrexate—bone cancer	0.000157	0.00122	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—bone cancer	0.000157	0.00122	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—bone cancer	0.000156	0.00122	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—bone cancer	0.000156	0.00122	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—bone cancer	0.000155	0.00121	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—bone cancer	0.000155	0.00121	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—bone cancer	0.000154	0.0012	CcSEcCtD
Carvedilol—CYP2E1—tendon—bone cancer	0.000154	0.00613	CbGeAlD
Carvedilol—Oedema peripheral—Doxorubicin—bone cancer	0.000154	0.0012	CcSEcCtD
Carvedilol—Angiopathy—Epirubicin—bone cancer	0.000153	0.00119	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—bone cancer	0.000153	0.00119	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—bone cancer	0.000152	0.00119	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—bone cancer	0.000152	0.00118	CcSEcCtD
Carvedilol—Back pain—Methotrexate—bone cancer	0.000152	0.00118	CcSEcCtD
Carvedilol—ADRA2A—spinal cord—bone cancer	0.000151	0.00604	CbGeAlD
Carvedilol—Visual impairment—Doxorubicin—bone cancer	0.00015	0.00117	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—bone cancer	0.000149	0.00116	CcSEcCtD
Carvedilol—Vomiting—Cisplatin—bone cancer	0.000148	0.00116	CcSEcCtD
Carvedilol—CYP2E1—spinal cord—bone cancer	0.000148	0.00591	CbGeAlD
Carvedilol—PTGS1—tendon—bone cancer	0.000148	0.0059	CbGeAlD
Carvedilol—Vision blurred—Methotrexate—bone cancer	0.000148	0.00115	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—bone cancer	0.000147	0.00115	CcSEcCtD
Carvedilol—Rash—Cisplatin—bone cancer	0.000147	0.00115	CcSEcCtD
Carvedilol—Dermatitis—Cisplatin—bone cancer	0.000147	0.00115	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—bone cancer	0.000147	0.00114	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—bone cancer	0.000145	0.00113	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—bone cancer	0.000145	0.00113	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—bone cancer	0.000145	0.00113	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—bone cancer	0.000144	0.00113	CcSEcCtD
Carvedilol—Tension—Epirubicin—bone cancer	0.000144	0.00112	CcSEcCtD
Carvedilol—PTGS1—spinal cord—bone cancer	0.000143	0.00569	CbGeAlD
Carvedilol—Nervousness—Epirubicin—bone cancer	0.000142	0.00111	CcSEcCtD
Carvedilol—Back pain—Epirubicin—bone cancer	0.000142	0.00111	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—bone cancer	0.000141	0.0011	CcSEcCtD
Carvedilol—Malaise—Methotrexate—bone cancer	0.000141	0.0011	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—bone cancer	0.000141	0.0011	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—bone cancer	0.000141	0.0011	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—bone cancer	0.000141	0.0011	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—bone cancer	0.00014	0.0011	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—bone cancer	0.00014	0.00109	CcSEcCtD
Carvedilol—Nausea—Cisplatin—bone cancer	0.000138	0.00108	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—bone cancer	0.000138	0.00108	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—bone cancer	0.000138	0.00107	CcSEcCtD
Carvedilol—Cough—Methotrexate—bone cancer	0.000137	0.00107	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—bone cancer	0.000136	0.00106	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—bone cancer	0.000136	0.00106	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—bone cancer	0.000136	0.00106	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—bone cancer	0.000136	0.00106	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—bone cancer	0.000134	0.00104	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—bone cancer	0.000133	0.00104	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—bone cancer	0.000133	0.00104	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—bone cancer	0.000133	0.00104	CcSEcCtD
Carvedilol—Tension—Doxorubicin—bone cancer	0.000133	0.00104	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000132	0.00103	CcSEcCtD
Carvedilol—Malaise—Epirubicin—bone cancer	0.000132	0.00103	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—bone cancer	0.000132	0.00103	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—bone cancer	0.000132	0.00103	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—bone cancer	0.000132	0.00103	CcSEcCtD
Carvedilol—Syncope—Epirubicin—bone cancer	0.000131	0.00103	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—bone cancer	0.000131	0.00102	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—bone cancer	0.000131	0.00102	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—bone cancer	0.00013	0.00102	CcSEcCtD
Carvedilol—Palpitations—Epirubicin—bone cancer	0.00013	0.00101	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—bone cancer	0.000129	0.00101	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—bone cancer	0.000129	0.00101	CcSEcCtD
Carvedilol—Cough—Epirubicin—bone cancer	0.000128	0.000998	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—bone cancer	0.000128	0.000997	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—bone cancer	0.000128	0.000997	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—bone cancer	0.000127	0.000991	CcSEcCtD
Carvedilol—Infection—Methotrexate—bone cancer	0.000127	0.000991	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—bone cancer	0.000127	0.000987	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—bone cancer	0.000126	0.000982	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—bone cancer	0.000125	0.000978	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—bone cancer	0.000125	0.000977	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—bone cancer	0.000125	0.000974	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—bone cancer	0.000125	0.000974	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—bone cancer	0.000125	0.000974	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—bone cancer	0.000124	0.000969	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000124	0.000967	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—bone cancer	0.000124	0.000964	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—bone cancer	0.000123	0.000962	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—bone cancer	0.000122	0.000954	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—bone cancer	0.000122	0.000952	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—bone cancer	0.000122	0.000951	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—bone cancer	0.000122	0.000951	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—bone cancer	0.000122	0.000949	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—bone cancer	0.000121	0.000947	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—bone cancer	0.000121	0.000941	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—bone cancer	0.00012	0.000935	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—bone cancer	0.00012	0.000933	CcSEcCtD
Carvedilol—Oedema—Epirubicin—bone cancer	0.00012	0.000933	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—bone cancer	0.000119	0.000932	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—bone cancer	0.000119	0.00093	CcSEcCtD
Carvedilol—Infection—Epirubicin—bone cancer	0.000119	0.000927	CcSEcCtD
Carvedilol—Cough—Doxorubicin—bone cancer	0.000118	0.000923	CcSEcCtD
Carvedilol—Shock—Epirubicin—bone cancer	0.000118	0.000918	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—bone cancer	0.000118	0.000917	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—bone cancer	0.000117	0.000914	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—bone cancer	0.000117	0.000914	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—bone cancer	0.000117	0.000911	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000116	0.000909	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—bone cancer	0.000116	0.000907	CcSEcCtD
Carvedilol—Hyperhidrosis—Epirubicin—bone cancer	0.000116	0.000902	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—bone cancer	0.000116	0.000902	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—bone cancer	0.000115	0.000901	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—bone cancer	0.000115	0.000901	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—bone cancer	0.000115	0.000901	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—bone cancer	0.000115	0.000896	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000115	0.000895	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—bone cancer	0.000114	0.00089	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—bone cancer	0.000114	0.00089	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—bone cancer	0.000114	0.000889	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—bone cancer	0.000114	0.000887	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—bone cancer	0.000113	0.000881	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—bone cancer	0.000113	0.000878	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—bone cancer	0.000112	0.000872	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—bone cancer	0.000112	0.000871	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—bone cancer	0.000111	0.000867	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—bone cancer	0.000111	0.000864	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—bone cancer	0.000111	0.000864	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—bone cancer	0.00011	0.000861	CcSEcCtD
Carvedilol—Fatigue—Methotrexate—bone cancer	0.00011	0.00086	CcSEcCtD
Carvedilol—Infection—Doxorubicin—bone cancer	0.00011	0.000858	CcSEcCtD
Carvedilol—Pain—Methotrexate—bone cancer	0.000109	0.000853	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000109	0.00085	CcSEcCtD
Carvedilol—Shock—Doxorubicin—bone cancer	0.000109	0.00085	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—bone cancer	0.000108	0.000846	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—bone cancer	0.000108	0.000844	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—bone cancer	0.000108	0.000843	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—bone cancer	0.000108	0.000839	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—bone cancer	0.000107	0.000838	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—bone cancer	0.000107	0.000835	CcSEcCtD
Carvedilol—Dyspnoea—Epirubicin—bone cancer	0.000107	0.000832	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—bone cancer	0.000106	0.00083	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—bone cancer	0.000106	0.000823	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—bone cancer	0.000105	0.000822	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—bone cancer	0.000105	0.000822	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—bone cancer	0.000105	0.000816	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—bone cancer	0.000104	0.000811	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—bone cancer	0.000103	0.000807	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—bone cancer	0.000103	0.000806	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—bone cancer	0.000103	0.000805	CcSEcCtD
Carvedilol—Pain—Epirubicin—bone cancer	0.000102	0.000798	CcSEcCtD
Carvedilol—Constipation—Epirubicin—bone cancer	0.000102	0.000798	CcSEcCtD
Carvedilol—Urticaria—Methotrexate—bone cancer	0.000102	0.000792	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—bone cancer	0.000101	0.000788	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—bone cancer	0.000101	0.000788	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000101	0.000787	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—bone cancer	0.0001	0.000781	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—bone cancer	9.94e-05	0.000776	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—bone cancer	9.87e-05	0.00077	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—bone cancer	9.86e-05	0.000769	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—bone cancer	9.84e-05	0.000768	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—bone cancer	9.78e-05	0.000763	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—bone cancer	9.75e-05	0.00076	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—bone cancer	9.62e-05	0.000751	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—bone cancer	9.56e-05	0.000746	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—bone cancer	9.55e-05	0.000745	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—bone cancer	9.51e-05	0.000742	CcSEcCtD
Carvedilol—Pain—Doxorubicin—bone cancer	9.47e-05	0.000739	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—bone cancer	9.47e-05	0.000739	CcSEcCtD
Carvedilol—Body temperature increased—Epirubicin—bone cancer	9.46e-05	0.000738	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—bone cancer	9.46e-05	0.000738	CcSEcCtD
Carvedilol—Hypersensitivity—Methotrexate—bone cancer	9.42e-05	0.000735	CcSEcCtD
Carvedilol—Asthenia—Methotrexate—bone cancer	9.17e-05	0.000716	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—bone cancer	9.12e-05	0.000712	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—bone cancer	9.05e-05	0.000706	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—bone cancer	9.05e-05	0.000706	CcSEcCtD
Carvedilol—Hypersensitivity—Epirubicin—bone cancer	8.82e-05	0.000688	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—bone cancer	8.8e-05	0.000686	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—bone cancer	8.75e-05	0.000683	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—bone cancer	8.75e-05	0.000683	CcSEcCtD
Carvedilol—Diarrhoea—Methotrexate—bone cancer	8.75e-05	0.000682	CcSEcCtD
Carvedilol—Asthenia—Epirubicin—bone cancer	8.59e-05	0.00067	CcSEcCtD
Carvedilol—ABCB1—bone marrow—bone cancer	8.47e-05	0.00338	CbGeAlD
Carvedilol—Pruritus—Epirubicin—bone cancer	8.47e-05	0.00066	CcSEcCtD
Carvedilol—Dizziness—Methotrexate—bone cancer	8.46e-05	0.00066	CcSEcCtD
Carvedilol—ABCB1—spinal cord—bone cancer	8.44e-05	0.00337	CbGeAlD
Carvedilol—Diarrhoea—Epirubicin—bone cancer	8.19e-05	0.000639	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—bone cancer	8.16e-05	0.000636	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—bone cancer	8.13e-05	0.000634	CcSEcCtD
Carvedilol—Rash—Methotrexate—bone cancer	8.06e-05	0.000629	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—bone cancer	8.05e-05	0.000628	CcSEcCtD
Carvedilol—Headache—Methotrexate—bone cancer	8.01e-05	0.000625	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—bone cancer	7.94e-05	0.00062	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—bone cancer	7.91e-05	0.000617	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—bone cancer	7.83e-05	0.000611	CcSEcCtD
Carvedilol—Vomiting—Epirubicin—bone cancer	7.61e-05	0.000593	CcSEcCtD
Carvedilol—Nausea—Methotrexate—bone cancer	7.59e-05	0.000592	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—bone cancer	7.58e-05	0.000591	CcSEcCtD
Carvedilol—Rash—Epirubicin—bone cancer	7.54e-05	0.000589	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—bone cancer	7.54e-05	0.000588	CcSEcCtD
Carvedilol—Headache—Epirubicin—bone cancer	7.5e-05	0.000585	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—bone cancer	7.32e-05	0.000571	CcSEcCtD
Carvedilol—Nausea—Epirubicin—bone cancer	7.11e-05	0.000554	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—bone cancer	7.04e-05	0.000549	CcSEcCtD
Carvedilol—Rash—Doxorubicin—bone cancer	6.98e-05	0.000545	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—bone cancer	6.97e-05	0.000544	CcSEcCtD
Carvedilol—Headache—Doxorubicin—bone cancer	6.94e-05	0.000541	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—bone cancer	6.58e-05	0.000513	CcSEcCtD
Carvedilol—ADRB3—Signaling Pathways—ATF1—bone cancer	2.49e-05	0.000166	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL3—bone cancer	2.49e-05	0.000165	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ATF1—bone cancer	2.49e-05	0.000165	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—GRM1—bone cancer	2.47e-05	0.000164	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NT5C3A—bone cancer	2.46e-05	0.000163	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—GNA11—bone cancer	2.45e-05	0.000163	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL3—bone cancer	2.45e-05	0.000163	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—GRM1—bone cancer	2.45e-05	0.000163	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL3—bone cancer	2.44e-05	0.000162	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NT5C3A—bone cancer	2.43e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL3—bone cancer	2.43e-05	0.000162	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL3—bone cancer	2.43e-05	0.000161	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL3—bone cancer	2.42e-05	0.000161	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—GRM1—bone cancer	2.42e-05	0.000161	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.42e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—GNA11—bone cancer	2.4e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL3—bone cancer	2.39e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—SMO—bone cancer	2.38e-05	0.000158	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RGS1—bone cancer	2.31e-05	0.000153	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GRM4—bone cancer	2.31e-05	0.000153	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—EGFR—bone cancer	2.29e-05	0.000152	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—GRM1—bone cancer	2.29e-05	0.000152	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL3—bone cancer	2.26e-05	0.00015	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—GRM1—bone cancer	2.25e-05	0.000149	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—JUN—bone cancer	2.25e-05	0.000149	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—GNA11—bone cancer	2.23e-05	0.000148	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL3—bone cancer	2.23e-05	0.000148	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.22e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—SMO—bone cancer	2.22e-05	0.000147	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—MMP9—bone cancer	2.19e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—GNA11—bone cancer	2.18e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL3—bone cancer	2.18e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.15e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RGS1—bone cancer	2.14e-05	0.000142	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GRM4—bone cancer	2.14e-05	0.000142	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.14e-05	0.000142	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—PLAU—bone cancer	2.1e-05	0.000139	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NT5C3A—bone cancer	2.08e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TGFBR2—bone cancer	2.08e-05	0.000138	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TGFBR2—bone cancer	2.08e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ENO2—bone cancer	2.03e-05	0.000135	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ENO2—bone cancer	2.03e-05	0.000135	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—GNA11—bone cancer	2.03e-05	0.000135	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL3—bone cancer	2.02e-05	0.000134	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GRM1—bone cancer	2e-05	0.000133	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL3—bone cancer	1.98e-05	0.000131	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IGF1R—bone cancer	1.96e-05	0.00013	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IGF1R—bone cancer	1.95e-05	0.00013	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NDUFA12—bone cancer	1.94e-05	0.000129	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.93e-05	0.000128	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SMO—bone cancer	1.91e-05	0.000127	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—bone cancer	1.89e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—DHFR—bone cancer	1.89e-05	0.000125	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—DHFR—bone cancer	1.88e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GRM1—bone cancer	1.86e-05	0.000123	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL3—bone cancer	1.84e-05	0.000122	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EGFR—bone cancer	1.77e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GNA11—bone cancer	1.76e-05	0.000117	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GNA11—bone cancer	1.76e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—GNA11—bone cancer	1.75e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SMO—bone cancer	1.74e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SMO—bone cancer	1.72e-05	0.000115	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SMO—bone cancer	1.7e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ENO2—bone cancer	1.65e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ATF1—bone cancer	1.62e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SMO—bone cancer	1.61e-05	0.000107	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NT5C3A—bone cancer	1.61e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CYP3A4—bone cancer	1.6e-05	0.000106	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CYP3A4—bone cancer	1.59e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—GNA11—bone cancer	1.59e-05	0.000106	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.59e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SMO—bone cancer	1.59e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL3—bone cancer	1.58e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—GNA11—bone cancer	1.58e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—GNA11—bone cancer	1.56e-05	0.000103	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—DHFR—bone cancer	1.53e-05	0.000102	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ENO2—bone cancer	1.52e-05	0.000101	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.52e-05	0.000101	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PTGS2—bone cancer	1.51e-05	0.0001	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—bone cancer	1.48e-05	9.85e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ATF1—bone cancer	1.48e-05	9.83e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—GNA11—bone cancer	1.47e-05	9.79e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ATF1—bone cancer	1.47e-05	9.74e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—GNA11—bone cancer	1.45e-05	9.63e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ATF1—bone cancer	1.45e-05	9.62e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL3—bone cancer	1.44e-05	9.59e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GNA11—bone cancer	1.43e-05	9.51e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL3—bone cancer	1.43e-05	9.5e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ENO2—bone cancer	1.43e-05	9.49e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KIT—bone cancer	1.42e-05	9.43e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KIT—bone cancer	1.42e-05	9.41e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL3—bone cancer	1.41e-05	9.38e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SMO—bone cancer	1.41e-05	9.36e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—DHFR—bone cancer	1.41e-05	9.34e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ATF1—bone cancer	1.37e-05	9.1e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GSTP1—bone cancer	1.37e-05	9.08e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GSTP1—bone cancer	1.36e-05	9.06e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFBR2—bone cancer	1.35e-05	9e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ATF1—bone cancer	1.35e-05	8.96e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL3—bone cancer	1.34e-05	8.87e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—BRAF—bone cancer	1.33e-05	8.86e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—BRAF—bone cancer	1.33e-05	8.84e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—DHFR—bone cancer	1.33e-05	8.81e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL3—bone cancer	1.31e-05	8.73e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GNA11—bone cancer	1.31e-05	8.73e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMO—bone cancer	1.31e-05	8.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CYP3A4—bone cancer	1.3e-05	8.62e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—bone cancer	1.29e-05	8.59e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GNA11—bone cancer	1.29e-05	8.56e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IGF1R—bone cancer	1.27e-05	8.47e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.27e-05	8.45e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GNA11—bone cancer	1.24e-05	8.23e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFBR2—bone cancer	1.23e-05	8.2e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFBR2—bone cancer	1.22e-05	8.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFBR2—bone cancer	1.21e-05	8.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ATF1—bone cancer	1.2e-05	7.96e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GNA11—bone cancer	1.2e-05	7.95e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CYP3A4—bone cancer	1.19e-05	7.92e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL3—bone cancer	1.17e-05	7.76e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IGF1R—bone cancer	1.16e-05	7.71e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IGF1R—bone cancer	1.15e-05	7.64e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	1.14e-05	7.59e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ENO2—bone cancer	1.14e-05	7.58e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IGF1R—bone cancer	1.14e-05	7.55e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	1.12e-05	7.47e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CYP3A4—bone cancer	1.12e-05	7.46e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.12e-05	7.43e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MDM2—bone cancer	1.12e-05	7.42e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MDM2—bone cancer	1.12e-05	7.41e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ATF1—bone cancer	1.11e-05	7.39e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—bone cancer	1.11e-05	7.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GSTP1—bone cancer	1.11e-05	7.37e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL3—bone cancer	1.09e-05	7.21e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ENO2—bone cancer	1.08e-05	7.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF1R—bone cancer	1.07e-05	7.14e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ENO2—bone cancer	1.07e-05	7.08e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—DHFR—bone cancer	1.06e-05	7.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF1R—bone cancer	1.06e-05	7.03e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—bone cancer	1.04e-05	6.9e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GSTP1—bone cancer	1.02e-05	6.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	9.99e-06	6.63e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—DHFR—bone cancer	9.98e-06	6.63e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GNA11—bone cancer	9.9e-06	6.57e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—DHFR—bone cancer	9.89e-06	6.57e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—JUN—bone cancer	9.71e-06	6.45e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—JUN—bone cancer	9.69e-06	6.44e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GSTP1—bone cancer	9.61e-06	6.38e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP9—bone cancer	9.45e-06	6.28e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP9—bone cancer	9.43e-06	6.27e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF1R—bone cancer	9.4e-06	6.24e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GNA11—bone cancer	9.33e-06	6.2e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	9.28e-06	6.16e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GNA11—bone cancer	9.25e-06	6.14e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KIT—bone cancer	9.24e-06	6.14e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO2—bone cancer	9.11e-06	6.05e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP3A4—bone cancer	8.97e-06	5.96e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF1R—bone cancer	8.73e-06	5.8e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—BRAF—bone cancer	8.69e-06	5.77e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP3A4—bone cancer	8.46e-06	5.62e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—DHFR—bone cancer	8.45e-06	5.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—bone cancer	8.44e-06	5.61e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KIT—bone cancer	8.42e-06	5.6e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—bone cancer	8.42e-06	5.59e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP3A4—bone cancer	8.38e-06	5.57e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KIT—bone cancer	8.35e-06	5.54e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.34e-06	5.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KIT—bone cancer	8.24e-06	5.47e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—BRAF—bone cancer	7.92e-06	5.26e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GNA11—bone cancer	7.9e-06	5.25e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—BRAF—bone cancer	7.84e-06	5.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KIT—bone cancer	7.8e-06	5.18e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—BRAF—bone cancer	7.74e-06	5.14e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GSTP1—bone cancer	7.67e-06	5.1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—bone cancer	7.67e-06	5.1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KIT—bone cancer	7.67e-06	5.1e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—bone cancer	7.64e-06	5.07e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—bone cancer	7.62e-06	5.06e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—bone cancer	7.6e-06	5.05e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—bone cancer	7.51e-06	4.99e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—BRAF—bone cancer	7.33e-06	4.87e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MDM2—bone cancer	7.28e-06	4.84e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTP1—bone cancer	7.23e-06	4.8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—BRAF—bone cancer	7.21e-06	4.79e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTP1—bone cancer	7.17e-06	4.76e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP3A4—bone cancer	7.16e-06	4.76e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.13e-06	4.73e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—bone cancer	7.1e-06	4.72e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—bone cancer	7.08e-06	4.7e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—bone cancer	7.06e-06	4.69e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO2—bone cancer	7.03e-06	4.67e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—bone cancer	6.99e-06	4.64e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KIT—bone cancer	6.81e-06	4.53e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MDM2—bone cancer	6.63e-06	4.41e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MDM2—bone cancer	6.57e-06	4.37e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—DHFR—bone cancer	6.52e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MDM2—bone cancer	6.49e-06	4.31e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—bone cancer	6.41e-06	4.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BRAF—bone cancer	6.41e-06	4.26e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—bone cancer	6.4e-06	4.25e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KIT—bone cancer	6.33e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—JUN—bone cancer	6.33e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—bone cancer	6.21e-06	4.12e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—bone cancer	6.16e-06	4.09e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MDM2—bone cancer	6.14e-06	4.08e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTP1—bone cancer	6.13e-06	4.07e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GNA11—bone cancer	6.1e-06	4.05e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MDM2—bone cancer	6.04e-06	4.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BRAF—bone cancer	5.95e-06	3.95e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—bone cancer	5.77e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—JUN—bone cancer	5.77e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—bone cancer	5.75e-06	3.82e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—JUN—bone cancer	5.71e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—JUN—bone cancer	5.64e-06	3.75e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—bone cancer	5.61e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—bone cancer	5.56e-06	3.69e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—bone cancer	5.49e-06	3.65e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MDM2—bone cancer	5.37e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—JUN—bone cancer	5.34e-06	3.55e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—bone cancer	5.28e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—JUN—bone cancer	5.25e-06	3.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—bone cancer	5.19e-06	3.45e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—bone cancer	5.11e-06	3.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MDM2—bone cancer	4.99e-06	3.31e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—bone cancer	4.98e-06	3.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—bone cancer	4.98e-06	3.31e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—bone cancer	4.73e-06	3.14e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—JUN—bone cancer	4.67e-06	3.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—bone cancer	4.54e-06	3.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—bone cancer	4.53e-06	3.01e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—bone cancer	4.49e-06	2.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—bone cancer	4.43e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JUN—bone cancer	4.33e-06	2.88e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—bone cancer	4.22e-06	2.8e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—bone cancer	4.2e-06	2.79e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—bone cancer	4.18e-06	2.78e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—bone cancer	4.13e-06	2.74e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—bone cancer	3.98e-06	2.64e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—bone cancer	3.81e-06	2.53e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—bone cancer	3.77e-06	2.51e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—bone cancer	3.75e-06	2.49e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—bone cancer	3.72e-06	2.47e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—bone cancer	3.71e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—bone cancer	3.67e-06	2.44e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—bone cancer	3.52e-06	2.34e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—bone cancer	3.47e-06	2.3e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—bone cancer	3.41e-06	2.26e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—bone cancer	3.17e-06	2.11e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—bone cancer	3.08e-06	2.05e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—bone cancer	2.86e-06	1.9e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—bone cancer	2.45e-06	1.63e-05	CbGpPWpGaD
